Bender, David
Hellerstein, David J. http://orcid.org/0000-0002-8031-4354
Article History
Received: 11 August 2021
Accepted: 20 December 2021
First Online: 13 January 2022
Declarations
:
: DB: no conflicts. DH: Dr. Hellerstein has received research funding support from Compass Pathways for psilocybin studies and from Pfizer, Lilly, Takeda, GeneSight, Marinus, Relmada, and IntraCellular Therapies for other studies. He is on the scientific advisory board for Reset Pharmaceuticals.